Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PharmaNet To Conduct Scancell SCIB1 Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

PharmaNet To Conduct Scancell SCIB1 Trial

PharmaNet Development Group has been selected to conduct and manage Scancell Ltd.’s Phase I/II trial with SCIB1 scheduled for 1H10.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PharmaNet Development Group has been selected to conduct and manage Scancell Ltd.’s Phase I/II trial with SCIB1 scheduled for 1H10. SCIB1 is a DNA ImmunoBody vaccine for the treatment of melanoma.

David Evans, chairman of Scancell, commented, “We are delighted to have selected PharmaNet to manage Scancell’s Phase I/II trial program with SCIB1. PharmaNet’s extensive experience, particularly in the management of early stage oncology clinical trials, will be of critical importance to Scancell as SCIB1 moves into clinical development.”

Jeffrey McMullen, president and chief executive officer, PharmaNet Development Group, commented, “This is our first project with Scancell. We are thrilled to work on Scancell’s innovative therapeutic cancer vaccine, SCIB1, and are very pleased that they have entrusted PharmaNet with their study.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics